A high overall response rate of 93% was observed for patients with immune thrombocytopenic purpura who received romiplostim biosimilar.
A single-center, retrospective data analysis in India evaluating safety and efficacy of biosimilar romiplostim (Romy) in patients with immune thrombocytopenic purpura (ITP) has demonstrated a high overall response rate (93%) without adverse events.
Romiplostim (Nplate) received US approval in 2008 for the treatment of ITP, which is characterized by an immune system attack on platelets that results in bruising, bleeding, and reddish-purple spots on the lower legs. The biosimilar Romy is approved in India but not in the United States.
Investigators enrolled 54 patients (male, 23; female, 31; median age, 40 years) with steroid-refractory or steroid-dependent ITP at the Haemato-Oncology Care Center in Vadodara, India, from July 2019 to January 2020. All patients had a pretreatment platelet count of less than 30,000/cmm. Romiplostim biosimilar was administered in a dose of 1 mcg/kg to 6 mcg/kg subcutaneously once a week.
Roughly 20% of patients (n = 12) had active bleeding and also received a concomitant rituximab 100 mg infusion once weekly for 4 weeks. For 51 patients, the overall response rate (ORR) with platelet count above 50,000 cmm; 4 patients (7%) had no response. Among patients who received rituximab with romiplostim, the ORR was 100% (12).
Investigators said the time to response was 1 week in 85% (46) of patients, and 16% (9) had a sustained response lasting more than 6 months even after discontinuing romiplostim at 4 weeks of therapy. They said 40% (21) had a sustained optimum response lasting more than 6 months with uninterrupted treatment. No patients experienced serious adverse events.
“Biosimilar romiplostim has shown rapid, excellent, and sustained response in the majority of ITP patients in our study,” said Seema S. Bhatwadekar, MD, MBBS, lead study author. “Its affordable cost [$160 per month] fulfills an unmet need for ITP patients requiring the best second line of treatment in India.”
Reference
Bhatwadekar SS, Deshpande SV, Khadse SV, et al. Efficacy and safety of biosimilar romiplostim in immune thrombocytopenic purpura: single centre retrospective data analysis. Presented at: 62nd American Society of Hematology Annual Meeting and Exposition; December 5-8, 2020. Abstract 2676.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Paving the Way for Equitable Biosimilar Access in Australian Dermatology Clinics
May 13th 2025Australia’s growing reliance on high-cost biologics for inflammatory skin diseases has placed significant pressure on its health system—but a new report suggests biosimilars could offer financial relief, provided uptake barriers are addressed through policy reform and education.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow
May 6th 2025Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.